501 research outputs found
Pulmonary vein reconnection and repeat ablation characteristics following cryoballoonâcompared to radiofrequencyâbased pulmonary vein isolation
Background: Despite advances in efficacy and safety of pulmonary vein isolation (PVI), atrial fibrillation (AF) recurrence after PVI remains common. PVâreconnection is the main finding during repeat PVI procedures performed to treat recurrent AF. Objective: To analyze pulmonary vein (PV) reconnection patterns during repeat ablation procedures in a large cohort of consecutive patients undergoing radio frequency or cryoballoonâbased PVI. Methods: Retrospective analysis of PVâreconnection patterns and analysis of reâablation strategies in consecutive index RFâ and CBâbased PVI and their respective reâablation procedures during concomitant usage of both energy sources at a single highâvolume center in Germany. Results: A total of 610 first (06/2015â10/2022) and 133 s (01/2016â11/2022) repeat ablation procedures after 363 (60%) RFâ and 247 (40%) CBâbased index PVIs between 01/2015 and 12/2021 were analyzed. PVâreconnection was found in 509/610 (83%) patients at first and 74/133 (56%) patients at second repeat procedure. 465 of 968 (48%) initially via CB isolated PVs were reconnected at first reâablation but 796 of 1422 initially RFâisolated PV (56%) were reconnected (OR: 0.73 [95% CI: 0.62â0.86]; p < .001). This was driven by fewer reconnections of the left PVs (LSPV: OR: 0.60 [95% CI: 0.42â0.86]; p = .005 and LSPV: 0.67 [0.47â0.95]; p = .026). PVâreconnection was more likely after longer, RFâbased index PVI and in older females. Repeat procedures were shorter after CBâcompared to after RFâPVI. Conclusions: Reconnection remains the most common reason for repeat AF ablation procedures after PVI. Our data suggest to preferentially use of the cryoballoon during index PVI, especially in older women
Pulmonary vein reconnection and repeat ablation characteristics following cryoballoonâcompared to radiofrequencyâbased pulmonary vein isolation
Background: Despite advances in efficacy and safety of pulmonary vein isolation (PVI), atrial fibrillation (AF) recurrence after PVI remains common. PVâreconnection is the main finding during repeat PVI procedures performed to treat recurrent AF. Objective: To analyze pulmonary vein (PV) reconnection patterns during repeat ablation procedures in a large cohort of consecutive patients undergoing radio frequency or cryoballoonâbased PVI. Methods: Retrospective analysis of PVâreconnection patterns and analysis of reâablation strategies in consecutive index RFâ and CBâbased PVI and their respective reâablation procedures during concomitant usage of both energy sources at a single highâvolume center in Germany. Results: A total of 610 first (06/2015â10/2022) and 133 s (01/2016â11/2022) repeat ablation procedures after 363 (60%) RFâ and 247 (40%) CBâbased index PVIs between 01/2015 and 12/2021 were analyzed. PVâreconnection was found in 509/610 (83%) patients at first and 74/133 (56%) patients at second repeat procedure. 465 of 968 (48%) initially via CB isolated PVs were reconnected at first reâablation but 796 of 1422 initially RFâisolated PV (56%) were reconnected (OR: 0.73 [95% CI: 0.62â0.86]; p < .001). This was driven by fewer reconnections of the left PVs (LSPV: OR: 0.60 [95% CI: 0.42â0.86]; p = .005 and LSPV: 0.67 [0.47â0.95]; p = .026). PVâreconnection was more likely after longer, RFâbased index PVI and in older females. Repeat procedures were shorter after CBâcompared to after RFâPVI. Conclusions: Reconnection remains the most common reason for repeat AF ablation procedures after PVI. Our data suggest to preferentially use of the cryoballoon during index PVI, especially in older women
Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation::The PREFER in AF - HF substudy
BACKGROUND AND OBJECTIVES: To assess thromboembolic and bleeding risks in patients with heart failure (HF) and atrial fibrillation (AF) according to HF type. METHODS: We analyzed 6170 AF patients from the Prevention of thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF), and categorized patients into: HF with reduced left-ventricular ejection fraction (HFrEF; LVEF60%), and no HF. Outcomes were ischemic stroke, major adverse cardiovascular and cerebral events (MACCE) and major bleeding occurring within 1-year. RESULTS: The annual incidence of stroke was linearly and inversely related to LVEF, increasing by 0.054% per each 1% of LVEF decrease (95% CI: 0.013%-0.096%; p=0.031). Patients with HFHpEF had the highest CHA2DS2-VASc score, but significantly lower stroke incidence than other HF groups (0.65%, compared to HFLpEF 1.30%; HFmrEF 1.71%; HFrEF 1.75%; trend p=0.014). The incidence of MACCE was also lower in HFHpEF (2.0%) compared to other HF groups (range: 3.8-4.4%; p=0.001). Age, HF type, and NYHA class were independent predictors of thromboembolic events. Conversely, major bleeding did not significantly differ between groups (p=0.168). CONCLUSION: Our study in predominantly anticoagulated patients with AF shows that, reduction in LVEF is associated with higher thromboembolic, but not higher bleeding risk. HFHpEF is a distinct and puzzling group, featuring the highest CHA2DS2-VASc score but the lowest residual risk of thromboembolic events, which warrants further investigation
Randomized Trials Fit for the 21st Century: A Joint Opinion From the European Society of Cardiology, American Heart Association, American College of Cardiology, and the World Heart Federation
Bilateral Remote Ischemic Conditioning in Children:a two-center, double-blind, randomized controlled trial in young children undergoing cardiac surgery
Objective: The study objective was to determine whether adequately delivered bilateral remote ischemic preconditioning is cardioprotective in young children undergoing surgery for 2 common congenital heart defects with or without cyanosis.Methods: We performed a prospective, double-blind, randomized controlled trial at 2 centers in the United Kingdom. Children aged 3 to 36 months undergoing tetralogy of Fallot repair or ventricular septal defect closure were randomized 1:1 to receive bilateral preconditioning or sham intervention. Participants were followed up until hospital discharge or 30 days. The primary outcome was area under the curve for high-sensitivity troponin-T in the first 24 hours after surgery, analyzed by intention-to-treat. Right atrial biopsies were obtained in selected participants.Results: Between October 2016 and December 2020, 120 eligible children were randomized to receive bilateral preconditioning (n = 60) or sham intervention (n = 60). The primary outcome, area under the curve for high-sensitivity troponin-T, was higher in the preconditioning group (mean: 70.0 ± 50.9 Όg/L/h, n = 56) than in controls (mean: 55.6 ± 30.1 Όg/L/h, n = 58) (mean difference, 13.2 Όg/L/h; 95% CI, 0.5-25.8; P = .04). Subgroup analyses did not show a differential treatment effect by oxygen saturations (pinteraction = .25), but there was evidence of a differential effect by underlying defect (pinteraction = .04). Secondary outcomes and myocardial metabolism, quantified in atrial biopsies, were not different between randomized groups.Conclusions: Bilateral remote ischemic preconditioning does not attenuate myocardial injury in children undergoing surgical repair for congenital heart defects, and there was evidence of potential harm in unstented tetralogy of Fallot. The routine use of remote ischemic preconditioning cannot be recommended for myocardial protection during pediatric cardiac surgery
Mitochondrial and Plasma Membrane Pools of Stomatin-Like Protein 2 Coalesce at the Immunological Synapse during T Cell Activation
Stomatin-like protein 2 (SLP-2) is a member of the stomatin â prohibitin â flotillin â HflC/K (SPFH) superfamily. Recent evidence indicates that SLP-2 is involved in the organization of cardiolipin-enriched microdomains in mitochondrial membranes and the regulation of mitochondrial biogenesis and function. In T cells, this role translates into enhanced T cell activation. Although the major pool of SLP-2 is associated with mitochondria, we show here that there is an additional pool of SLP-2 associated with the plasma membrane of T cells. Both plasma membrane-associated and mitochondria-associated pools of SLP-2 coalesce at the immunological synapse (IS) upon T cell activation. SLP-2 is not required for formation of IS nor for the re-localization of mitochondria to the IS because SLP-2-deficient T cells showed normal re-localization of these organelles in response to T cell activation. Interestingly, upon T cell activation, we found the surface pool of SLP-2 mostly excluded from the central supramolecular activation complex, and enriched in the peripheral area of the IS where signalling TCR microclusters are located. Based on these results, we propose that SLP-2 facilitates the compartmentalization not only of mitochondrial membranes but also of the plasma membrane into functional microdomains. In this latter location, SLP-2 may facilitate the optimal assembly of TCR signalosome components. Our data also suggest that there may be a net exchange of membrane material between mitochondria and plasma membrane, explaining the presence of some mitochondrial proteins in the plasma membrane
Use of mechanical circulatory support in patients with non-ischaemic cardiogenic shock
Aims Despite its high incidence and mortality risk, there is no evidence-based treatment for non-ischaemic cardiogenic shock (CS). The aim of this study was to evaluate the use of mechanical circulatory support (MCS) for non-ischaemic CS treatment.Methods and results In this multicentre, international, retrospective study, data from 890 patients with non-ischaemic CS, defined as CS due to severe de-novo or acute-on-chronic heart failure with no need for urgent revascularization, treated with or without active MCS, were collected. The association between active MCS use and the primary endpoint of 30-day mortality was assessed in a 1:1 propensity-matched cohort. MCS was used in 386 (43%) patients. Patients treated with MCS presented with more severe CS (37% vs. 23% deteriorating CS, 30% vs. 25% in extremis CS) and had a lower left ventricular ejection fraction at baseline (21% vs. 25%). After matching, 267 patients treated with MCS were compared with 267 patients treated without MCS. In the matched cohort, MCS use was associated with a lower 30-day mortality (hazard ratio 0.76, 95% confidence interval 0.59-0.97). This finding was consistent through all tested subgroups except when CS severity was considered, indicating risk reduction especially in patients with deteriorating CS. However, complications occurred more frequently in patients with MCS; e.g. severe bleeding (16.5% vs. 6.4%) and access-site related ischaemia (6.7% vs. 0%).Conclusion In patients with non-ischaemic CS, MCS use was associated with lower 30-day mortality as compared to medical therapy only, but also with more complications. Randomized trials are needed to validate these findings.[GRAPHICS
A stakeholder co-design approach for developing a community pharmacy service to enhance screening and management of atrial fibrillation
The authors would like to thank all participants in this research for their
valuable input into the co-design process.Background: Community pharmacies provide a suitable setting to promote self-screening programs aimed at
enhancing the early detection of atrial fibrillation (AF). Developing and implementing novel community pharmacy
services (CPSs) is a complex and acknowledged challenge, which requires comprehensive planning and the
participation of relevant stakeholders. Co-design processes are participatory research approaches that can enhance
the development, evaluation and implementation of health services. The aim of this study was to co-design a
pharmacist-led CPS aimed at enhancing self-monitoring/screening of AF.
Methods: A 3-step co-design process was conducted using qualitative methods: (1) interviews and focus group
with potential service users (n = 8) to identify key needs and concerns; (2) focus group with a mixed group of
stakeholders (n = 8) to generate a preliminary model of the service; and (3) focus group with community pharmacy
owners and managers (n = 4) to explore the feasibility and appropriateness of the model. Data were analysed
qualitatively to identify themes and intersections between themes. The JeMa2 model to conceptualize pharmacybased
health programs was used to build a theoretical model of the service.
Results: Stakeholders delineated: a clear target population (i.e., individuals â„65 years old, with hypertension, with or
without previous AF or stroke); the components of the service (i.e., patient education; self-monitoring at home;
results evaluation, referral and follow-up); and a set of circumstances that may influence the implementation of the
service (e.g., quality of the service, competency of the pharmacist, inter-professional relationships, etc.). A number of
strategies were recommended to enable implementation (e.g.,. endorsement by leading cardiovascular
organizations, appropriate communication methods and channels between the pharmacy and the general medical
practice settings, etc.).
Conclusion: A novel and preliminary model of a CPS aimed at enhancing the management of AF was generated
from this participatory process. This model can be used to inform decision making processes aimed at adopting
and piloting of the service. It is expected the co-designed service has been adapted to suit existing needs of
patients and current care practices, which, in turn, may increase the feasibility and acceptance of the service when
it is implemented into a real setting.This work was funded by Covidien Pty Ltd. (Medtronic Australasia Pty Ltd)
[UTS Project code: PRO16â0688], which is the company that has the rights to distribute the device Microlife BP A200 AFIB in Australia. Also, funding for
this research has been provided by a UTS Chancellorâs postdoctoral
fellowship awarded to the first author of this article (ID number:
2013001605)
FGF4 Independent Derivation of Trophoblast Stem Cells from the Common Vole
The derivation of stable multipotent trophoblast stem (TS) cell lines from preimplantation, and early postimplantation mouse embryos has been reported previously. FGF4, and its receptor FGFR2, have been identified as embryonic signaling factors responsible for the maintenance of the undifferentiated state of multipotent TS cells. Here we report the derivation of stable TS-like cell lines from the vole M. rossiaemeridionalis, in the absence of FGF4 and heparin. Vole TS-like cells are similar to murine TS cells with respect to their morphology, transcription factor gene expression and differentiation in vitro into derivatives of the trophectoderm lineage, and with respect to their ability to invade and erode host tissues, forming haemorrhagic tumours after subcutaneous injection into nude mice. Moreover, vole TS-like cells carry an inactive paternal X chromosome, indicating that they have undergone imprinted X inactivation, which is characteristic of the trophoblast lineage. Our results indicate that an alternative signaling pathway may be responsible for the establishment and stable proliferation of vole TS-like cells
Progression From Paroxysmal to Persistent Atrial Fibrillation. Clinical Correlates and Prognosis
Objectives: We investigated clinical correlates of atrial fibrillation (AF) progression and evaluated the prognosis of patients demonstrating AF progression in a large population. Background: Progression of paroxysmal AF to more sustained forms is frequently seen. However, not all patients will progress to persistent AF. Methods: We included 1,219 patients with paroxysmal AF who participated in the Euro Heart Survey on AF and had a known rhythm status at follow-up. Patients who experienced AF progression after 1 year of follow-up were identified. Results: Progression of AF occurred in 178 (15%) patients. Multivariate analysis showed that heart failure, age, previous transient ischemic attack or stroke, chronic obstructive pulmonary disease, and hypertension were the only independent predictors of AF progression. Using the regression coefficient as a benchmark, we calculated the HATCH score. Nearly 50% of the patients with a HATCH score >5 progressed to persistent AF compared with only 6% of the patients with a HATCH score of 0. During follow-up, patients with AF progression were more often admitted to the hospital and had more major adverse cardiovascular events. Conclusions: A substantial number of patients progress to sustained AF within 1 year. The clinical outcome of these patients regarding hospital admissions and major adverse cardiovascular events was worse compared with patients demonstrating no AF progression. Factors known to cause atrial structural remodeling (age and underlying heart disease) were independent predictors of AF progression. The HATCH score may help to identify patients who are likely to progress to sustained forms of AF in the near future. \ua9 2010 American College of Cardiology Foundation
- âŠ